Cantor Fitzgerald Forecasts JANX FY2025 Earnings

Janux Therapeutics, Inc. (NASDAQ:JANX) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Janux Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings of ($2.95) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $200.00 price target on the stock. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.38) per share.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The firm had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The company’s quarterly revenue was down 82.6% compared to the same quarter last year.

Other analysts also recently issued research reports about the stock. BTIG Research boosted their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. Leerink Partners boosted their price objective on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research note on Tuesday, December 3rd. Stifel Nicolaus boosted their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Finally, HC Wainwright boosted their price objective on shares of Janux Therapeutics from $63.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $89.90.

Janux Therapeutics Trading Down 1.8 %

Shares of NASDAQ:JANX opened at $40.18 on Wednesday. The company has a market capitalization of $2.11 billion, a PE ratio of -34.34 and a beta of 3.23. Janux Therapeutics has a twelve month low of $7.79 and a twelve month high of $71.71. The firm has a 50 day simple moving average of $52.36 and a 200-day simple moving average of $48.37.

Insider Transactions at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 13,334 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total value of $731,769.92. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $4,507,788.32. The trade was a 13.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO David Alan Campbell sold 5,000 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total transaction of $300,000.00. Following the completion of the transaction, the chief executive officer now owns 293,054 shares in the company, valued at approximately $17,583,240. This trade represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 108,334 shares of company stock valued at $6,070,020 in the last ninety days. 29.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in JANX. Amalgamated Bank lifted its holdings in Janux Therapeutics by 61.1% in the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after purchasing an additional 368 shares in the last quarter. Plato Investment Management Ltd lifted its holdings in Janux Therapeutics by 18.7% in the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after purchasing an additional 187 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares in the last quarter. Avanza Fonder AB purchased a new position in Janux Therapeutics in the 4th quarter valued at about $139,000. Finally, AQR Capital Management LLC purchased a new position in Janux Therapeutics in the 2nd quarter valued at about $215,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.